9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2009 KiSS1 treatment of pancreatic adenocarcinoma NIH Principal Investigator
2. 2009 Pre-clinical studies of DR5 mediated therapy of TNBC, None Principal Investigator
3. 2009 Vector targeted genetic radiotherapy NIH/NCI Principal Investigator
4. 2009 Targeted fusion protein for prostate cancer therapy DOD Principal Investigator
5. 2009 Voltage-gated sodium channel subtype 1.7-specific blockers for the treatment of prostate cancer NIH Principal Investigator
6. 2009 Pancreatic cancer therapy with DR5 mAb and apoptosis modulators NIH Principal Investigator
7. 2009 Design and development of novel non-toxic, multivalent, and biocompatible nano-polymers for tumor-targeted delivery of antibreast cancer drugs DOD Principal Investigator
8. 2009 Treatment of triple negative breast cancer stem cells with TRA-8 anti-DR5 monoclonal mntibody DOD Principal Investigator
9. 2009 Treatment of TN breast cancer stem cells with TRA-8 anti-DR5 monoclonal antibody NIH Principal Investigator
10. 2009 SPORE in pancreatic cancer NIH Principal Investigator
11. 2009 SPORE in pancreatic cancer---Project #2: Combined modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies NIH Basic Co-Leader
12. 2009 SPORE in pancreatic cancer Administrative Supplement NIH Principal Investigator
13. 2009 Therapy of glioblastoma with DR5 mAb and apoptosis modulators National Brain Tumor Society Principal Investigator
14. 2009 Pectin-based microbeads for targeted delivery of imaging and anti-cancer agents NIH Principal Investigator
15. 2006 2008 Mechanisms and therapeutic efficacy of combination TRA-8, anti-DR5 monoclonal antibody, and chemotherapy in breast cancer DOD Principal Investigator
16. 2006 2008 UAB/Sankyo Program for Rheumatic Diseases and Cancer Research, Sankyo Co., Ltd Principal Investigator
17. 2007 A novel target to enhance chemosensitivity in pancreatic cancer ACS Principal Investigator
18. 2007 Death receptor-mediated apoptosis and therapy strategies in ovarian cancer NIH Principal Investigator
19. 2007 SPORE in breast cancer: DR5 antibody treatment of breast cancer stem cells NIH Basic Co-Leader
20. 2005 2007 Research study and material transfer agreement MGI Pharma, Inc Principal Investigator
21. 2005 2007 DNA-pki Program Luitpold Pharmaceuticals, Inc Principal Investigator
22. 2005 2007 Ascenta Research Agreement Ascenta Therapeutics, Inc Principal Investigator
23. 2002 2007 Research training program in surgical oncology NIH Principal Investigator
24. 2002 2007 Molecular therapeutics for anaplastic gliomas NIH Principal Investigator
25. 2006 Role of DDX3 in DR-mediated apoptosis NIH Principal Investigator
26. 2004 2006 UAB/Sankyo Program for Rheumatic Diseases and Cancer Research Sankyo Co., Ltd Principal Investigator
27. 2002 2006 Paclitaxel-monoclonal antibody conjugates for targeted chemotherapy of breast cancer DOD Principal Investigator
28. 2002 2006 Radiosensitization with recombinant antibodies to EGFr NIH Principal Investigator
29. 2001 2006 Paclitaxel-monoclonal antibody conjugates for targeted therapy of prostate cancer DOD Principal Investigator
30. 2000 2006 SPORE in Breast Cancer, Kirby I. Bland, Principal Investigator NIH Project Leader
31. 1999 2006 SPORE in ovarian cancer, Edward E. Partridge NIH Co-Project Leader
32. 2005 Comprehensive Cancer Center Core Support Grant NIH-NCI Co-Leader
33. 2005 Molecular therapeutics for anaplastic gliomas NIH Principal Investigator
34. 2003 2005 Research study and material transfer agreement Guilford Pharmaceuticals, Inc Principal Investigator
35. 2003 2005 Development of novel radiopharmaceuticals for somatostatin receptor therapy DOE Principal Investigator
36. 2002 2005 Radioimmunotoxin therapy of experimental colon and ovarian cancer DOE Principal Investigator
37. 2002 2005 Treatment of breast cancer with antibodies against DR4 and DR5 receptors in combination with chemotherapy DOD Principal Investigator
38. 2003 2004 Enhancement of glioma radiation therapy and chemotherapy response with targeted antibody therapy against death receptor 5 ABC2 Principal Investigator
39. 2002 2004 TM-601 pilot animal efficacy studies TransMolecular, Inc.- Principal Investigator
40. 2002 2004 UAB/Sankyo Program for Rheumatic Diseases and Cancer Research, Treatment of cancer with death receptor antibodies in combination with chemotherapy and radiation therapy Sankyo Co., Ltd Principal Investigator
41. 2001 2004 Genetic radiotherapy of prostate cancer DOD Principal Investigator
42. 1999 2004 In vivo image analysis of autoreactive T cells NIH Principal Investigator
43. 2003 SPORE in pancreatic cancerSPORE in pancreatic cancer Multi-modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies and chemotherapy NIH Project Leader
44. 2001 2003 Taxane conjugates for targeted therapy of cancer UABRF/NaPro BioTherapeutics, Inc Principal Investigator
45. 2000 2003 Radiopharmaceutical and gene therapy program DOE Principal Investigator
46. 1999 2003 An In vivo reporter system for imaging gene transfer NIH Principal Investigator
47. 2001 2002 SPORE-Multi-modality treatment of pancreatic cancer UNMC Principal Investigator
48. 2001 2002 Prostate cancer specific adenoviral vectors to increase the therapeutic index of targeted radiotherapy DOE Principal Investigator
49. 2001 2002 UAB/Sankyo Program for Rheumatic Diseases Research Sankyo Co., Ltd Principal Investigators
50. 2000 2002 Treatment of hormone-refractory prostate cancer with radiolabeled peptides ACS Principal Investigator
51. 2000 2002 Novel radioimmunotherapy for ovarian cancer NIH Principal Investigator
52. 1999 2002 Evaluation of Ch2 deleted HuCC49 for intraperitoneal RIT NIH Principal Investigator.
53. 1999 2002 Selective transduction for early detection and therapy of cancer NIH Principal Investigator.
54. 1999 2002 Combined therapy with C225 antibody, chemotherapy, and external beam radiation for colon cancer ImClone Systems, Inc Principal Investigator
55. 1999 2002 New BCAs for radioimmunotherapy with radiometals NIH Principal Investigator
56. 1999 2002 Radioimmunotoxin therapy of experimental human colon and ovarian cancer DOE Principal Investigator
57. 2000 2001 Capital equipment for pretargeting and angiogenesis research program Cancer Center Principal Investigator
58. 2000 2001 Breast cancer research and care program Avon Foundation Principal Investigator
59. 1999 2001 SPORE in ovarian cancer NIH Principal Investigator
60. 1999 2000 PACLIMER delivery system: Radiosensitization studies Guilford Pharmaceuticals, Inc
61. 1998 2000 Radiopharmaceutical and gene therapy program DOE Principal Investigator
62. 1998 2000 Genetic radioimmunotherapy of pancreatic cancer NIH Principal Investigator
63. 1998 2000 Single chain antibody-mediated gene knockout for radiosensitivity ACS Principal Investigator
64. 1997 2000 Radiopharmaceutical and gene therapy program DOE Principal Investigator
65. 1999 1999 Testing of 99mTc-RP527 in AdCMVGRPr transfected A427 tumors Resolution Pharmaceuticals, Inc Principal Investigator
66. 1996 1999 Radioimmunotoxin therapy of experimental human gastrointestinal cancer DOE Principal Investigator
67. 1996 1998 New BCAs for radioimmunotherapy with radiometals NIH Principal Investigator
68. 1994 1998 Treatment of colon cancer with radiolabeled antibody NIH Principal Investigator
69. 1997 1997 Alpha radiotherapy via pretargeted lead-212 NIH Principal Investigator
70. 1993 1997 Radiopharmaceutical and gene therapy program DOE Principal Investigator
71. 1992 1997 Clinical oncology research career development program NIH Principal Investigator
72. 1993 1996 Radioimmunotoxin therapy of experimental human gastrointestinal cancer DOE Principal Investigator
73. 1994 1995 Alabama Project Definition Study for the National Biomedical Tracer Facility DOE Principal Investigator
74. 1994 1994 Proposal to document tissue antigen distribution, tumor localization and potential therapeutic efficacy of human anti-glioma monoclonal antibody BT32/A6 Novopharm Biotech Principal Investigator
75. 1990 1993 Treatment of colon cancer with radiolabeled CEA antibody NIH Principal Investigator
76. 1987 1991 Radiopharmaceuticals for the diagnosis and treatment of cancer NIH Principal Investigator
77. 1988 1990 Therapy of experimental human leukemia/lymphoma using radioimmunotoxins ACS Principal Investigator
78. 1988 1989 Biomedical Research Support Grant-Radiolabeled antibody therapy of B-cell lymphoma University of Michigan Medical School Principal Investigator
79. 1987 1989 Treatment of colon cancer with radiolabeled CEA antibody NIH Principal Investigator
80. 1987 1987 Diagnosis and therapy of squamous cancer using monoclonal antibody A9 University of Michigan Cancer Center Principal Investigator
81. 1987 1987 Regional delivery of monoclonal antibodies to colon carcinoma University of Michigan Cancer Center Principal Investigator
82. 1986 1987 Special appropriation from Department of Human Resources, State of Georgia, Localization and treatment of colon and rectal cancer with radiolabeled CEA antibody Medical Research Foundation, Inc., Atlanta, Georgia


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.